News
PLSE
27.10
+13.11%
3.14
Pulse Biosciences Q1 FY26 net loss widens to $18.58 million
PUBT · 14h ago
Pulse Biosciences Co-Chairman Purchase $13.3 Million In Company Stock
NASDAQ · 2d ago
Pulse Bio rises after over $13M insider buying
Seeking Alpha · 2d ago
Pulse Biosciences announces ATM equity purchases by co-chairmen
TipRanks · 2d ago
Pulse Biosciences Co‑Chairmen, CEO Purchase ~$13.3M In Shares Via ATM Program
Benzinga · 2d ago
Pulse Biosciences co-chairmen buy shares worth about $13.3 million
PUBT · 2d ago
ATM EQUITY PURCHASES BY PULSE BIOSCIENCES’ CO-CHAIRMEN TOTAL APPROXIMATELY $13.3 MILLION
Reuters · 2d ago
Massive Insider Buying Spree at Pulse Biosciences Sparks Investor Buzz
TipRanks · 3d ago
Pulse Bio CEO Paul LaViolette acquires $295,350 common shares
PUBT · 3d ago
Pulse Biosciences director Robert W. Duggan acquires 660,233 shares for $13 million
PUBT · 3d ago
Weekly Report: what happened at PLSE last week (0504-0508)?
Weekly Report · 3d ago
Pulse Biosciences Races Ahead on AF Trial Momentum
TipRanks · 6d ago
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
Barchart · 6d ago
Pulse Biosciences Authorizes Insider Purchases Under Equity Program
TipRanks · 05/06 13:36
PLSE Q4 2025 Earnings Transcript
NASDAQ · 05/04 20:32
Pulse Biosciences Highlights Q1 Results, Electrophysiology Focus
TipRanks · 05/04 13:50
Earnings Scheduled For May 4, 2026
Benzinga · 05/04 11:11
Pulse Biosciences reports Q1 EPS (27c) vs (25c) last year
TipRanks · 05/04 11:10
Pulse Biosciences records Q1 revenue, but loss widens on higher clinical investment
Reuters · 05/04 11:09
Pulse Biosciences GAAP EPS of -$0.27 beats by $0.05, revenue of $0.4M in-line
Seeking Alpha · 05/04 11:09
More
Webull provides a variety of real-time PLSE stock news. You can receive the latest news about Pulse Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About PLSE
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.